image-cmn-bg-banner

May 20, 2025

On May 12, 2025, Biogen Inc., represented by Willkie, settled its issuance and sale of $400,000,000 aggregate principal amount 5.050% Senior Notes Due 2031, $650,000,000 aggregate principal amount 5.750% Senior Notes Due 2035, and $700,000,000 aggregate principal amount 6.450% Senior Notes Due 2055. The joint book-runners on the offering were BofA Securities, Inc., Citigroup Global Markets Inc. J.P. Morgan Securities LLC, Deutsche Bank Securities Inc., Mizuho Securities USA LLC, Morgan Stanley & Co. LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC.

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. It has a broad portfolio of medicines to treat multiple sclerosis, introduced the first approved treatment for spinal muscular atrophy, co-developed treatments to address a defining pathology of Alzheimer’s disease, and launched the first approved treatment to target a genetic cause of amyotrophic lateral sclerosis. 

The Willkie team was led by partners Howard Block and John Ablan and included associates Margaret O’Brien and Katherine Sears. Partner Anne Barrett provided advice on corporate matters and partner Guy Inbar and associate Shay Moyal provided tax counsel.